The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in rats

International Journal of Cardiology

Volumn 167, Issue 1, 2013, Pages 87-93

  Hocher, Berthold ^a,b   Sharkovska, Yuliya ^b,c   Mark, Michael ^d   Klein, Thomas ^d   Pfab, Thiemo ^b,c  

^a UNIVERSITY OF POTSDAM   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Cardiac ischemia reperfusion; Dipeptidylpeptidase 4; Infarct size; Myocardial ischemia; Rats; Stromal cell derived factor 1

Indexed keywords

8 (3 AMINO 1 PIPERIDINYL) 7 (2 BUTYN 1 YL) 1 [(4,6 DIMETHYL 2 PYRIMIDINYL)METHYL] 3 METHYLXANTHINE; BI 14361; CD34 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; LINAGLIPTIN; STROMAL CELL DERIVED FACTOR 1ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY LIGATION; ARTICLE; CELL COUNT; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENZYME INHIBITION; HEART CATHETERIZATION; HEART FUNCTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE DP-DT; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; WISTAR RAT;

ANIMALS; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; PURINES; QUINAZOLINES; RANDOM ALLOCATION; RATS; RATS, WISTAR; XANTHINES;

EID: 84878587722     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2011.12.007     Document Type: Article

References (33)

1. A. Leri, J. Kajstura, P. Anversa, and W.H. Frishman Myocardial regeneration and stem cell repair Curr Probl Cardiol 33 2008 91 153
2. E. Deindl, M.M. Zaruba, and S. Brunner G-CSF administration after myocardial infarction in mice attenuates late ischemic cardiomyopathy by enhanced arteriogenesis FASEB J 20 2006 956 958
3. D. Orlic, J. Kajstura, and S. Chimenti Bone marrow cells regenerate infarcted myocardium Nature 410 2001 701 705
4. H. Ince, M. Petzsch, and H.D. Kleine Prevention of left ventricular remodeling with granulocyte colony-stimulating factor after acute myocardial infarction: final 1-year results of the Front-Integrated Revascularization and Stem Cell Liberation in Evolving Acute Myocardial Infarction by Granulocyte Colony-Stimulating Factor (FIRSTLINE-AMI) Trial Circulation 112 2005 I73 I80
5. K.C. Wollert, G.P. Meyer, and J. Lotz Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial Lancet 364 2004 141 148
6. S. Fazel, M. Cimini, and L. Chen Cardioprotective c-kit + cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines J Clin Invest 116 2006 1865 1877
7. T. Kinnaird, E. Stabile, M.S. Burnett, and S.E. Epstein Bone-marrow-derived cells for enhancing collateral development: mechanisms, animal data, and initial clinical experiences Circ Res 95 2004 354 363
8. D.J. Ceradini, A.R. Kulkarni, and M.J. Callaghan Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1 Nat Med 10 2004 858 864
9. A.T. Askari, S. Unzek, and Z.B. Popovic Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy Lancet 362 2003 697 703
10. K.W. Christopherson, G. Hangoc, C.R. Mantel, and H.E. Broxmeyer Modulation of hematopoietic stem cell homing and engraftment by CD26 Science 305 2004 1000 1003
11. J. Huhn, S. Ehrlich, B. Fleischer, and A. von Bonin Molecular analysis of CD26-mediated signal transduction in T cells Immunol Lett 72 2000 127 132
12. P. Ruiz, N. Zacharievich, A.L. Viciana, and M. Shenkin Peripheral CD34 + progenitor cells express CD26 and contain increased dipeptidyl peptidase IV activity Acta Haematol 100 1998 110 112
13. C. Durinx, A.M. Lambeir, and E. Bosmans Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides Eur J Biochem 267 2000 5608 5613
14. V.F. Segers, T. Tokunou, L.J. Higgins, C. MacGillivray, J. Gannon, and R.T. Lee Local delivery of protease-resistant stromal cell derived factor-1 for stem cell recruitment after myocardial infarction Circulation 116 2007 1683 1692
15. D.J. Drucker, and M.A. Nauck The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 368 2006 1696 1705
16. D.J. Drucker The biology of incretin hormones Cell Metab 3 2006 153 165
17. A.K. Bose, M.M. Mocanu, R.D. Carr, and D.M. Yellon Myocardial ischaemia-reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway Cardiovasc Drugs Ther 21 2007 253 256
18. M.H. Noyan-Ashraf, M.A. Momen, and K. Ban GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice Diabetes 58 2009 975 983
19. L. Timmers, J.P. Henriques, and D.P. de Kleijn Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury J Am Coll Cardiol 53 2009 501 510
20. M. Sauve, K. Ban, and M.A. Momen Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice Diabetes 59 2010 1063 1073
21. M.M. Zaruba, H.D. Theiss, and M. Vallaster Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction Cell Stem Cell 4 2009 313 323
22. Y. Ye, K.T. Keyes, C. Zhang, J.R. Perez-Polo, Y. Lin, and Y. Birnbaum The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA Am J Physiol Heart Circ Physiol 298 2010 H1454 H1465
23. L. Thomas, M. Eckhardt, E. Langkopf, M. Tadayyon, F. Himmelsbach, and M. Mark (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazoli n-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors PLoS One 6 11 2011 e27861
24. N.G. Frangogiannis The mechanistic basis of infarct healing Antioxid Redox Signal 8 2006 1907 1939
25. K. Miyagishima, S. Hiramitsu, and H. Kimura Long term prognosis of chronic heart failure: reduced vs preserved left ventricular ejection fraction Circ J 73 2009 92 99
26. S.D. Roes, S. Kelle, and T.A. Kaandorp Comparison of myocardial infarct size assessed with contrast-enhanced magnetic resonance imaging and left ventricular function and volumes to predict mortality in patients with healed myocardial infarction Am J Cardiol 100 2007 930 936
27. E. Wu, J.T. Ortiz, and P. Tejedor Infarct size by contrast enhanced cardiac magnetic resonance is a stronger predictor of outcomes than left ventricular ejection fraction or end-systolic volume index: prospective cohort study Heart 94 2008 730 736
28. D. Zhang, W. Huang, and B. Dai Genetically manipulated progenitor cell sheet with diprotin A improves myocardial function and repair of infarcted hearts Am J Physiol Heart Circ Physiol 299 2010 H1339 H1347
29. A. Aiuti, I.J. Webb, C. Bleul, T. Springer, and J.C. Gutierrez-Ramos The chemokine SDF-1 is a chemoattractant for human CD34 + hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34 + progenitors to peripheral blood J Exp Med 185 1997 111 120
30. A. Behfar, L.V. Zingman, and D.M. Hodgson Stem cell differentiation requires a paracrine pathway in the heart FASEB J 16 2002 1558 1566
31. Y.S. Yoon, A. Wecker, and L. Heyd Clonally expanded novel multipotent stem cells from human bone marrow regenerate myocardium after myocardial infarction J Clin Invest 115 2005 326 338
32. R. Frederich, J.H. Alexander, and F.T. Fiedorek A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes Postgrad Med 122 2010 16 27
33. L. Chaykovska, K. von Websky, and J. Rahnenführer Effects of DPP-4 Inhibitors on the Heart in a Rat Model of Uremic Cardiomyopathy PLoS ONE 6 11 2011 e27861 doi: 10.1371/journal.pone.0027861